Williams, Geraint P. and Radford, C and Nightingale, Peter and Dart, J K G and Rauz, Saaeha (2011) Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. Eye, 25 (9). pp. 1207-1218. ISSN 0950-222X
URL of Published Version: http://dx.doi.org/10.1038/eye.2011.175
Identification Number/DOI: doi:10.1038/eye.2011.175
PURPOSE: Ocular mucous membrane pemphigoid (OcMMP) is a sight-threatening autoimmune disease in which referral to specialists units for further management is a common practise. This study aims to describe referral patterns, disease phenotype and management strategies in patients who present with either early or established disease to two large tertiary care hospitals in the United Kingdom.
PATIENTS AND METHODS: In all, 54 consecutive patients with a documented history of OcMMP were followed for 24 months. Two groups were defined: (i) early-onset disease (EOD:<3 years, n=26, 51 eyes) and (ii) established disease (EstD:>5 years, n=24, 48 eyes). Data were captured at first clinic visit, and at 12 and 24 months follow-up. Information regarding duration, activity and stage of disease, visual acuity (VA), therapeutic strategies and clinical outcome were analysed.
RESULTS: Patients with EOD were younger and had more severe conjunctival inflammation (76% of inflamed eyes) than the EstD group, who had poorer VA (26.7%=VA<3/60, P<0.01) and more advanced disease. Although 40% of patients were on existing immunosuppression, 48% required initiation or switch to more potent immunotherapy. In all, 28% (14) were referred back to the originating hospitals for continued care. Although inflammation had resolved in 78% (60/77) at 12 months, persistence of inflammation and progression did not differ between the two phenotypes. Importantly, 42% demonstrated disease progression in the absence of clinically detectable inflammation.
CONCLUSIONS: These data highlight that irrespective of OcMMP phenotype, initiation or escalation of potent immunosuppression is required at tertiary hospitals. Moreover, the conjunctival scarring progresses even when the eye remains clinically quiescent. Early referral to tertiary centres is recommended to optimise immunosuppression and limit long-term ocular damage.
|Type of Work:||Article|
|School/Faculty:||Colleges (2008 onwards) > College of Medical & Dental Sciences|
|Department:||School of Immunity and Infection|
|Keywords:||cicatrising conjunctivitis; conjunctival scarring; progression; immunosuppression |
|Institution:||University of Birmingham|
|Copyright Holders:||The Royal College of Ophthalmologists, Nature Publishing Group, The authors|
Repository Staff Only: item control page